Achaogen Inc. Daily Stock Analysis

Daily Stock Analysis, AKAO, Achaogen Inc, priceseries

Achaogen Inc. Daily Stock Analysis
Stock Information
Open
0.11
Close
0.11
High
0.19
Low
0.10
Previous Close
0.12
Daily Price Gain
-0.01
YTD High
2.11
YTD High Date
Jan 4, 2019
YTD Low
0.06
YTD Low Date
Apr 26, 2019
YTD Price Change
-1.15
YTD Gain
-91.27%
52 Week High
13.48
52 Week High Date
Jun 21, 2018
52 Week Low
0.06
52 Week Low Date
Apr 26, 2019
52 Week Price Change
-12.98
52 Week Gain
-99.16%
Recent priceSeries Trade Signals

These are sample algorithmic trades based on actual market data.

Trade Type
Entry Date
Entry Price
Exit Date
Exit Price
Trade Hold Time
Gain
Trade Record
LONG
Jan 10. 2017
15.46
Jan 25. 2017
17.04
10 Trading Days
10.22%
Link
LONG
Feb 1. 2017
16.83
Mar 14. 2017
25.06
28 Trading Days
48.92%
Link
LONG
Jan 25. 2019
1.38
Feb 1. 2019
1.47
5 Trading Days
6.88%
Link
Company Information
Stock Symbol
AKAO
Exchange
NasdaqGM
Company URL
http://www.achaogen.com
Company Phone
650-800-3636
CEO
Kenneth J. Hillan
Headquarters
California
Business Address
7000 SHORELINE COURT, SUITE 371, SOUTH SAN FRANCISCO, CA 94080
Sector
Equity
Industry Category
Drugs
Industry Group
Biotechnology
CIK
0001301501
About

Achaogen, Inc. operates as a clinical-stage biopharmaceutical company, which engaegs in discovering, developing, and commercializing novel antibacterials to treat multi-drug resistant (MDR) gram-negative infections. It also offers plazomicin for the treatment of serious bacterial infections. The company was by Ian R. Friedland and Nathaniel E. David founded in June 2002 and is headquartered in South San Francisco, CA.

Description

Achaogen, Inc., a late-stage biopharmaceutical company, discovers, develops, and commercializes antibacterials to treat multi-drug resistant (MDR) gram-negative infections in the United States. The company is principally developing plazomicin, which is in Phase III clinical trial for the treatment of serious bacterial infections, including urinary tract infections, blood stream infections, and other infections due to MDR Enterobacteriaceae comprising carbapenem-resistant Enterobacteriaceae. It is also involved in the research and development of antipseudomonal LpxC inhibitor compounds for the treatment of bacterial infections; and therapeutic antibody discovery program. The company has license and collaboration agreements with Thermo Fisher Scientific, Inc. to develop and commercialize an assay to to enable patients to receive safe and efficacious doses of plazomicin; Crystal Biosciences, Inc. to discover monoclonal antibodies against multiple targets; Ionis Pharmaceuticals, Inc. for certain patents relating to aminoglycoside antibacterial compounds and related know-how to develop and commercialize certain novel aminoglycoside antibacterial compounds; and Hovione Limited to manufacture the active pharmaceutical ingredient for plazomicin. The company was incorporated in 2002 and is based in South San Francisco, California.

TCHANNELS® is a Registered Trademark with USPTO

Some images used on this site have been taken from Unsplash

Legal Information

Useful Links

Contact Us

PO Box 2574, Sunnyvale
California 94087-0574, USA
Phone: 408-940-5056
Email: Click to send us an Email

Risks of Algorithmic Trading: Before investing please read our disclosure on Risks of Algorithmic Trading.

DISCLAIMER All investments entail inherent risk. This research seeks to assist investors in determining when to buy and when to sell to attempt to maximize profits or minimize losses. All final investment decisions are yours and as a result you could make or lose money. priceSeries.com, its employees and/or its affiliates and family members may from time to time take positions in the open market or otherwise with respect to the securities discussed. priceSeries.com, its employees and/or affiliates do not have stock ownership equal to or greater than 1% of the outstanding stock of the covered company nor does any employee of priceSeries.com sit on the Board of Directors of any covered company. priceSeries.com is not a broker/dealer, and the firm does not underwrite securities, manage assets or perform investment banking activities. The statements made herein include information obtained from sources believed to be reliable, but no independent verification has been made and we do not guarantee its accuracy or completeness.

U.S. Government Required Disclaimer - Commodity Futures Trading Commission
Futures and Options trading has large potential rewards, but also large potential risk. You must be aware of the risks and be willing to accept them in order to invest in the futures and options markets. Don't trade with money you can't afford to lose. This is neither a solicitation nor an offer to Buy/Sell futures or options. No representation is being made that any account will or is likely to achieve profits or losses similar to those discussed on this web site. The past performance of any trading system or methodology is not necessarily indicative of future results.

CFTC RULE 4.41 - HYPOTHETICAL OR SIMULATED PERFORMANCE RESULTS HAVE CERTAIN LIMITATIONS. UNLIKE AN ACTUAL PERFORMANCE RECORD, SIMULATED RESULTS DO NOT REPRESENT ACTUAL TRADING. ALSO, SINCE THE TRADES HAVE NOT BEEN EXECUTED, THE RESULTS MAY HAVE UNDER-OR-OVER COMPENSATED FOR THE IMPACT, IF ANY, OF CERTAIN MARKET FACTORS, SUCH AS LACK OF LIQUIDITY. SIMULATED TRADING PROGRAMS IN GENERAL ARE ALSO SUBJECT TO THE FACT THAT THEY ARE DESIGNED WITH THE BENEFIT OF HINDSIGHT. NO REPRESENTATION IS BEING MADE THAT ANY ACCOUNT WILL OR IS LIKELY TO ACHIEVE PROFIT OR LOSSES SIMILAR TO THOSE SHOWN.

2016 © priceSeries.com All Rights Reserved. Privacy Policy | Subscriber Agreement | Risks of Algorithmic Trading